We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novo Nordisk Sues Biocon for Patent infringement Over Blockbuster Weight Loss and Diabetes Drugs
Novo Nordisk Sues Biocon for Patent infringement Over Blockbuster Weight Loss and Diabetes Drugs
Novo Nordisk is going after Biocon Pharma, claiming patent infringement over a generic version of Novo’s weight loss drug Saxenda (liraglutide injection), a glucagon-like peptide-1 (GLP-1) receptor agonist.